Enavate Sciences GP, LLC — 13F Holdings & Portfolio

CIK 1953107 · latest 13F-HR filed 2026-08-14

Enavate Sciences GP, LLC manages $345.4M in 13F-reported U.S. long-equity assets across 7 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are SION (31.56%), ZBIO (28.80%), IMNM (22.17%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 0 new positions and exited 0; 2 existing positions rose in reported value and 4 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$345.4M

Long-equity book

Holdings
7

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+0 / −0 / ↑2 / ↓4

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 100%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

Show all 2 →

New Positions

  • No new positions this quarter.
Show all 0 →

Exited Positions

  • No exits this quarter.
Show all 0 →

Enavate Sciences GP, LLC Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 SIONNA THERAPEUTICS INC SION 829401108 $109.0M 31.56% 2,478,030 SH
2 ZENAS BIOPHARMA INC ZBIO 98937L105 $99.5M 28.80% 3,919,159 SH
3 IMMUNOME INC IMNM 45257U108 $76.6M 22.17% 3,613,799 SH
4 BRIDGEBIO ONCOLOGY THERAPEUT BBOT 107924102 $20.0M 5.80% 2,626,946 SH
5 COMPASS THERAPEUTICS INC CMPX 20454B104 $17.1M 4.94% 7,788,150 SH
6 UPSTREAM BIO INC UPB 91678A107 $17.0M 4.93% 2,459,703 SH
7 CAMP4 THERAPEUTICS CORP CAMP 13463J101 $6.2M 1.80% 1,425,541 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $345.4M 7 0001953107-26-000012
2026-03-31 2026-05-15 $351.5M 7 0001953107-26-000008
2025-12-31 2026-02-17 $506.8M 7 0001953107-26-000003
2025-09-30 2025-11-14 $327.5M 7 0001953107-25-000014
Filer Information
Address
106 W 56TH ST.
FLOOR 8
NEW YORK, NY 10019
Phone
(212) 909-3022
Filing Manager
ENAVATE SCIENCES GP, LLC
New York, NY
Signatory
James P. Boylan
Chief Executive Officer